Precancerous conditions of the vulva

Last medical review:

Precancerous conditions of the vulva are changes to vulvar cells that make them more likely to develop into cancer. These conditions are not yet cancer. But if they aren’t treated, there is a chance that these abnormal changes will become vulvar cancer.

Vulvar intraepithelial neoplasia (VIN)

Vulvar intraepithelial neoplasia (VIN) means abnormal changes to the epithelial cells in the top or surface layer of skin that covers the vulva. VIN is also known as lower anogenital squamous intraepithelial lesion.

There are 2 types of VIN based on whether or not they are linked to human papillomavirus (HPV) infection.

HPV-associated VIN, also known as usual-type VIN, is linked to HPV infection. It’s the most common type of VIN. It’s more common in people aged 35 to 55.

HPV-associated VIN is divided into 2 subtypes based on its grade.

  • Low-grade squamous intraepithelial lesion (LSIL) is usually caused by an infection with a low-risk type of HPV, such as type 6 or 11. It normally goes away on its own and doesn’t cause cancer. LSIL used to be called VIN 1.
  • High-grade squamous intraepithelial lesion (HSIL) is usually caused by an infection with a high-risk type of HPV, such as type 16, 18, 31 or 33. HSIL can become cancer, so it often requires treatment. HSIL used to be called VIN 2 or VIN 3.

If an HPV-associated VIN develops into cancer, it becomes the basaloid or warty squamous cell carcinoma (SCC) of the vulva.

HPV-independent VIN, also known as differentiated-type VIN (d-VIN), is less common. It usually occurs in older people aged 55 to 85.

HPV-independent VIN is not linked to HPV infection, but it often occurs when there is lichen sclerosus (a skin condition). Lichen sclerosus can make skin itchy and cause white patches due to inflammation. The skin may also become thinner and paler than usual. The vulva may look abnormal.

If HPV-independent VIN develops into cancer, it becomes keratinizing SCC of the vulva. HPV-independent VIN tends to develop into cancer faster than HPV-associated VIN.

Risk factors

The following risks increase your chance of developing VIN:

  • HPV infection
  • lichen sclerosus
  • smoking
  • immunosuppression

Find out more about HPV.

Symptoms

Up to 40% of VIN cases don’t cause symptoms. They are diagnosed when having tests for other health problems.

The signs and symptoms of VIN include:

  • itching in the vulva that doesn’t go away or get better over time
  • soreness, burning or severe tingling in the vulva that can become worse when urinating
  • some areas of the vulvar skin appearing white, red, pink, gray, brown or black
  • thickened vulvar skin
  • discomfort or pain during sex caused by ulcers and nodules on the skin

Diagnosis

If you have symptoms or your doctor thinks you might have VIN, you will be sent for tests. Tests used to diagnose VIN may include:

  • an examination of the vulva, vagina, cervix and anus
  • a colposcopy of any abnormal areas of the vulva
  • a biopsy

Treatments

Treatment options for VIN include:

  • no active treatment with close follow-up (watchful waiting)
  • topical therapy (an ointment or cream) such as imiquimod (Aldara, Zyclara) or fluorouracil (5-fluorouracil or 5-FU)
  • laser surgery to burn the abnormal cells away
  • a wide local excision to remove the area of skin affected by VIN and some healthy tissue around it (called the surgical margin)

Find out more about surgery for vulvar cancer.

Follow-up after treatment for VIN

If you have been treated for VIN, there is a risk that it will come back (recur). You will have regular follow-up visits, usually every few months. These visits will happen less often if there are no problems. Report any concerns and signs or symptoms to the doctor without waiting for your next scheduled visit.

Expert review and references

  • Alon Altman, H.BSc., MD, FRCSC, CCPE
  • American Cancer Society. Topical Therapy for Vulvar Pre-Cancer. 2018. https://www.cancer.org/.
  • Provincial Health Services Authority. Vulva. 2020. http://www.bccancer.bc.ca/.
  • Cancer Research UK. Vulval Intraepithelial Neoplasia (VIN). 2023. https://www.cancerresearchuk.org/.
  • Capria A, Tahir N, Fatehi M. Vulvar cancer. StatPearls [Internet]. StatPearls Publishing; 2023. https://www.statpearls.com/.
  • Cleveland Clinic. Vulvar Intraepithelial Neoplasia. 2023. https://my.clevelandclinic.org/.
  • Höhn AK, Brambs CE, Hiller GGR. 2020 WHO classification of female genital tumors. Geburtshilfe und Frauenheilkunde. 2021: 81(10):1145–1153.
  • Ling DC, Beriwal S. Vulvar cancer: etiology, risk factors, genetics, and molecular biology. Chi DS, Khabele D, Dizon DS, Yasha C, eds.. Principles and Practice of Gynecologic Oncology. 8th ed. Philadelphia, PA: Wolters Kluwer; 2025: Kindle versoin, chapter 2.3.
  • Ling DC, Beriwal S. Therapy for vulvar cancer: radiation, systemic therapy, and treatment of persistent and recurrent disease. Chi DS, Khabele D, Dizon DS, Yasha C, eds.. Principles and Practice of Gynecologic Oncology. 8th ed. Philadelphia, PA: Wolters Kluwer; 2025: Kindle version, chapter 2.6.
  • Macmillan Cancer Support. Vulval cancer. 2021. https://www.macmillan.org.uk/.
  • Macmillan Cancer Support. Vulval Intraepithelial Neoplasia (VIN). 2021. https://www.macmillan.org.uk/.
  • Musunuru HB, Vargo JA, Olawaiye AB, Beriwal S. Cancer of the vagina and vulva. DeVita VT Jr, Lawrence TS, Rosenberg S. eds. DeVita Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Philadelphia, PA: Wolters Kluwer; 2023: Kindle version, chapter 49, https://read.amazon.ca/?asin=B0BG3DPT4Q&language=en-CA.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Vulvar Cancer. Version 4.2024. 2024. https://www.nccn.org/home.
  • Olawaiye AB, Cuello MA, Rogers LJ. Cancer of the vulva: 2021 update. International Journal of Gynecology & Obstetrics. 2021: 155 Suppl 1(Suppl 1):7–18.
  • van der Kolk WL, Oonk MHM. Vulvar cancer: clinical presentation, diagnostic evaluation, and workup. Chi DS, Khabele D, Dizon DS, Yasha C, eds.. Principles and Practice of Gynecologic Oncology. 8th ed. Philadelphia, PA: Wolters Kluwer; 2025: Kindle version, chapter 2.5.
  • van der Kolk WL. Vulvar cancer: preinvasive disease. Chi DS, Khabele D, Dizon DS, Yasha C, eds.. Principles and Practice of Gynecologic Oncology. 8th ed. Philadelphia, PA: Wolters Kluwer; 2025: Kindle versoin, chapter 2.4.

Your trusted source for accurate cancer information

With support from readers like you, we can continue to provide the highest quality cancer information for over 100 types of cancer.

We’re here to ensure easy access to accurate cancer information for you and the millions of people who visit this website every year. But we can’t do it alone.

Every donation helps fund reliable cancer information, compassionate support services and the most promising research. Please give today because every contribution counts. Thank you.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2025 Canadian Cancer Society